These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8908651)

  • 1. The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group".
    Bruun E; Frimodt-Møller C
    Scand J Urol Nephrol; 1996 Aug; 30(4):291-7. PubMed ID: 8908651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
    Klioze SS; Miller MF; Spiro TP
    Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
    Krongrad A; Brady J; Rodriguez RJ
    South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buserelin treatment of advanced prostatic cancer: a phase II study.
    Veronesi A; Lo Re G; Dal Bo V; Magri MD; Della Valentina M; Talamini R; Merlo A; Francini M; Monfardini S
    Med Oncol Tumor Pharmacother; 1989; 6(4):255-7. PubMed ID: 2515400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Orchiectomy and buserelin in combination with flutamide: comparative results in metastatic prostatic carcinoma].
    Mora MJ; Extramiana J; Paniagua P; González P; Mañas A; Pérez MJ; Navarro J; Arrizabalaga M
    Actas Urol Esp; 1991; 15(6):548-52. PubMed ID: 1792994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.
    Huben RP; Murphy GP
    Cancer; 1988 Nov; 62(9):1881-7. PubMed ID: 3139279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate?
    Samdal F; Vada K; Lundmo PI; Mjølnerød OK
    Scand J Urol Nephrol; 1991; 25(3):197-9. PubMed ID: 1835129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome.
    Koutsilieris M; Faure N; Tolis G; Laroche B; Robert G; Ackman CF
    Urology; 1986 Mar; 27(3):221-8. PubMed ID: 3082058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
    Falkson G; Vorobiof DA
    J Clin Oncol; 1987 Sep; 5(9):1419-23. PubMed ID: 3114438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 17. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
    Soloway MS; Chodak G; Vogelzang NJ; Block NL; Schellhammer PF; Smith JA; Scott M; Kennealey G; Gau TC
    Urology; 1991 Jan; 37(1):46-51. PubMed ID: 1824732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.